# Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma

> **NCT05970666** · PHASE2 · RECRUITING · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 71 (estimated)

## Conditions studied

- Adebrelimab
- Hepatocellular Carcinoma
- Transformation
- Bevacizumab
- TACE

## Interventions

- **DRUG:** TACE with adebrelimab and bevacizumab

## Key facts

- **NCT ID:** NCT05970666
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-15
- **Primary completion:** 2026-11-15
- **Final completion:** 2026-11-15
- **Target enrollment:** 71 (ESTIMATED)
- **Last updated:** 2024-02-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05970666

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05970666, "Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05970666. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*